PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31215459-0	2019	Pharmacological profiling of a dual FAK/IGF-1R kinase inhibitor TAE226 in cellular and in vivo tumor models.	TAE226	64-70	insulin-like growth factor I receptor	Mus musculus	40-46	
31215459-7	2019	In the MIA PaCa-2 model, TAE226 inhibited phosphorylation of Y397-FAK and phosphorylation of S473-Akt as IGF-1R signaling in the cell culture in vitro and the tumor in mice.	TAE226	25-31	insulin-like growth factor I receptor	Mus musculus	105-111	
27531475-0	2016	[Therapeutic effect of IGF-1R-targeting inhibitor (TAE226) on malignant pleural effusion in nude mice].	TAE226	51-57	insulin-like growth factor I receptor	Mus musculus	23-29	
27531475-1	2016	OBJECTIVE: To study the therapeutic effect of IGF-1R inhibitor TAE226 on malignant pleural effusion (MPE) in nude mice.	TAE226	63-69	insulin-like growth factor I receptor	Mus musculus	46-52	
26090892-1	2015	TAE226, a bis-anilino pyrimidine compound, has been developed as an inhibitor of focal adhesion kinase (FAK) and insulin-like growth factor-I receptor (IGF-IR).	TAE226	0-6	insulin-like growth factor I receptor	Mus musculus	113-150	
26090892-1	2015	TAE226, a bis-anilino pyrimidine compound, has been developed as an inhibitor of focal adhesion kinase (FAK) and insulin-like growth factor-I receptor (IGF-IR).	TAE226	0-6	insulin-like growth factor I receptor	Mus musculus	152-158